Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies.
Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies.
复制标题
DOI：
10.1016/j.leukres.2013.07.034
复制
发表时间：
2013-11
影响因子：
2.7
通讯作者：
Lancet JE
中科院分区：
文献类型：
--
作者：
Sampath D;Malik A;Plunkett W;Nowak B;Williams B;Burton M;Verstovsek S;Faderl S;Garcia-Manero G;List AF;Sebti S;Kantarjian HM;Ravandi F;Lancet JE
Akt, a serine/threonine protein kinase, is constitutively phosphorylated and hyperactivated in multiple cancers, including acute myeloid leukemia. High levels are linked to poor survival and inferior responses to chemotherapy, making Akt inhibition an attractive therapeutic target. In this phase I/II study of TCN-PM, a small-molecule Akt inhibitor, TCN-PM therapy was well tolerated in patients with advanced hematological malignancies, and reduced levels of phosphorylation of Akt and its substrate Bad were shown, consistent with inhibition of this survival pathway and induction of cell death. Further investigation of TCN-PM alone or in combination in patients with high Akt levels is warranted.
登录
查看更多内容
影响因子：
20.3
作者：
Kornblau, Steven M.;Womble, Matthew;Andreeff, Michael
通讯作者：
Andreeff, Michael
影响因子：
56.9
作者：
Franke, TF;Kaplan, DR;Toker, A
通讯作者：
Toker, A
DOI：
10.1158/1078-0432.ccr-10-2544
发表时间：
2011-05-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Balasis ME;Forinash KD;Chen YA;Fulp WJ;Coppola D;Hamilton AD;Cheng JQ;Sebti SM
通讯作者：
Sebti SM
DOI：
10.1158/1078-0432.ccr-09-2551
发表时间：
2010-03-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Kornblau SM;Singh N;Qiu Y;Chen W;Zhang N;Coombes KR
通讯作者：
Coombes KR
影响因子：
3.4
作者：
Garrett CR;Coppola D;Wenham RM;Cubitt CL;Neuger AM;Frost TJ;Lush RM;Sullivan DM;Cheng JQ;Sebti SM
通讯作者：
Sebti SM